Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy-Reference-Cited by-同舟云学术

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy

Published:2009-03-01 Issue:5 Volume:115 Page:981-987
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Choueiri Toni K.,Xie Wanling,D'Amico Anthony V.,Ross Robert W.,Hu Jim C.,Pomerantz Mark,Regan Meredith M.,Taplin Mary-Ellen,Kantoff Philip W.,Sartor Oliver,Oh William K.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference12 articles.

1. Drug insight: role of the androgen receptor in the development and progression of prostate cancer;Taplin;Nat Clin Pract Oncol.,2007

2. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy;D'Amico;N Engl J Med.,2004

3. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy;D'Amico;JAMA.,2005

4. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy;Zhou;J Clin Oncol.,2005

5. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162);Hussain;J Clin Oncol.,2006

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Akkermansia muciniphila Metabolite Inosine Inhibits Castration Resistance in Prostate Cancer;Microorganisms;2024-08-12

2. Independent association between prostate-specific antigen nadir and PSA progression-free survival in first-line abiraterone acetate treatment in castration-resistant prostate cancer patients: a pilot study;Frontiers in Oncology;2024-06-04

3. Prognostic significance of nadir PSA value and time to nadir PSA in patients with metastatic castration-naive prostate cancer receiving first-line hormonotherapy;Journal of Cancer Research and Therapeutics;2023-12-15

4. Low PSA radiographic disease progression on C11‐choline PET;BJUI Compass;2023-10-25

5. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study;European Urology Oncology;2023-10